An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer

By Scagliotti Giorgio  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2855-2866

Informa Healthcare

Access to resources Recommend Favorite

Pemetrexed: Potential Role in the Adjuvant Chemotherapy of Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 78-84

Bentham Science Publishers

Access to resources Recommend Favorite

Pemetrexed in advanced non-small cell lung cancer

By Gridelli Cesare   Maione Paolo   Rossi Antonio   Bareschino Maria Anna   Schettino Clorinda   Sacco Paola Claudia   Zeppa Rosario  

Expert Opinion on Drug Safety, Vol. 10, Iss. 2, 2011-03 ,pp. : 311-317

Informa Healthcare

Access to resources Recommend Favorite

Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy

By  

Current Clinical Pharmacology, Vol. 13, Iss. 2, 2018-05 ,pp. : 76-84

Bentham Science Publishers

Access to resources Recommend Favorite

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

By Doebele Robert C.   Spigel David   Tehfe Mustapha   Thomas Sachdev   Reck Martin   Verma Sunil   Eakle Janice   Bustin Frederique   Goldschmidt Jerome   Cao Dachuang   Alexandris Ekaterine   Yurasov Sergey   Camidge D. Ross   Bonomi Philip  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 883-892

Blackwell Publishing

Access to resources Recommend Favorite